Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
166 entries « 1 of 17 »

Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Journal Article

Eur Urol, 85 (2), 2024.

| Links:

Nguyen DD, Mousa A, Klotz L, Niazi T, Pouliot F, Kokorovic A, Lavallée LT, Huynh M, Lapointe N, Di Risio M, Wallis CJD

Screening and management of metabolic, cardiac, and bone health in prostate cancer patients on androgen deprivation therapy A survey of specialized physicians

Journal Article

Can Urol Assoc J, 18 (6), 2024.

| Links:

Graham J, Ghosh S, Breau RH, Wood L, Tanguay S, Bosse D, Lalani AK, Bhindi B, Heng D, Finelli A, Fallah-Rad N, Castonguay V, Basappa NS, Soulières D, Pouliot F, Kollmannsberger C, Bjarnason GA

Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

Journal Article

Clin Genitourin Cancer, 22 (3), 2024.

Abstract | Links:

Chi KN, Yip SM, Bauman G, Probst S, Emmenegger U, Kollmannsberger CK, Martineau P, Niazi T, Pouliot F, Rendon R, Hotte SJ, Laidley DT, Saad F

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Journal Article

Curr Oncol, 31 (3), 2024.

Abstract | Links:

Saad F, Hotte SJ, Noonan K, Malone S, Morash C, Niazi T, Rendon RA, Shayegan B, Basappa NS, Cagiannos I, Danielson B, Delouya G, Fernandes R, Ferrario C, Finelli A, Gotto GT, Hamilton RJ, Izard JP, Kapoor A, Lalani AK, Lavallée LT, Ong M, Pouliot F, So AI, Yip S, Chi KN

Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum

Journal Article

Can Urol Assoc J, 18 (4), 2024.

Abstract | Links:

Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC

Journal Article

Can Urol Assoc J, 18 (2), 2024.

Abstract | Links:

Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É, Castonguay V, Marcoux N, Lodde M, Juneau D, Hamilou Z, Lattouf JB, Buteau FA, Pavic M, Castilloux JF, Neveu B, Bouvet GF, Allard C, Tétu A, Guérin B, Beauregard JM,

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

Journal Article

J Nucl Med, 2024.

Abstract | Links:

Lemire F, Zhang M, Anderson P, Finelli A, Rendon RA, Tanguay S, Bansal R, Bhindi B, So AI, Pouliot F, Dean L, Mallick R, Lavallée LT, Breau RH

The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors

Journal Article

Can Urol Assoc J, 18 (2), 2024.

Abstract | Links:

Touma N, Pouliot F

Response to the Letter to the Editor

Journal Article

Prostate, 2024.

| Links:

Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Journal Article

Eur Urol Oncol, 7 (3), 2024.

Abstract | Links:

166 entries « 1 of 17 »
Signaler des ajouts ou des modifications

Active projects

  • 3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer), from 2018-03-07 to 2029-03-31
  • Analyse des vésicules extracellulaires dans le sang des hommes atteints d’un cancer de la prostate : utilité dans la stadification de la maladie et la réponse au traitement., from 2024-05-01 to 2027-05-01
  • Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2025-06-30
  • Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy, from 2023-03-31 to 2025-03-31
  • Projet de recherche sur le cancer de la prostate intitulé Ironman , from 2020-03-24 to 2025-03-31
  • Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
  • Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities, from 2022-10-01 to 2027-09-30

Recently finished projects

  • Imagerie moléculaire relié au cancer de la prostate, from 2023-02-01 to 2024-01-31
  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30
Data provided by the Université Laval research projects registery